A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

Concurrently, Genmab is embroiled in a legal dispute with AbbVie Inc (NYSE:ABBV)., which has accused the company of misappropriating trade secrets related to antibody-drug conjugates. Genmab has ...

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.

Also Read: AbbVie/Genmab’s Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway The trial included 502 patients, 101 of which were Japanese.

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the eleventh Annual Genedata Partner Symposium (March 31?April 1 ...

Genmab A/S, a biotechnology company ... The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...